Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Mullally

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Hematology. American Society of Hematology. Education Program|February 20, 2015
How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?Edwin Chen, Ann Mullally
Journal of Cellular and Molecular Medicine|August 8, 2023
Antibody targeting of mutant calreticulin in myeloproliferative neoplasmsFrederike Kramer, Ann Mullally
Current Hematologic Malignancy Reports|November 6, 2022
Molecular Pathogenesis of Myeloproliferative NeoplasmsBenjamin Rolles, Ann Mullally
Blood|September 30, 2006
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantationAnn Mullally, Jerome Ritz
Hematology. American Society of Hematology. Education Program|December 4, 2018
JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapyMichele Ciboddo, Ann Mullally
Cell Stem Cell|September 10, 2013
Sinister symbiosis: pathological hematopoietic-stromal interactions in CMLAnn Mullally, Benjamin L Ebert
Journal of Visualized Experiments : Jove|January 25, 2018
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic CellsNouran S Abdelfattah, Ann Mullally
Blood|February 5, 2017
Myeloproliferative neoplasm stem cellsAdam J Mead, Ann Mullally
Blood|November 8, 2014
Hit the spleen, JAK!Steven W Lane, Ann Mullally
Frontiers in Immunology|September 28, 2020
Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPNJonas Samuel Jutzi, Ann Mullally
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Hematology. American Society of Hematology. Education Program|February 20, 2015
How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?Edwin Chen, Ann Mullally
Journal of Cellular and Molecular Medicine|August 8, 2023
Antibody targeting of mutant calreticulin in myeloproliferative neoplasmsFrederike Kramer, Ann Mullally
Current Hematologic Malignancy Reports|November 6, 2022
Molecular Pathogenesis of Myeloproliferative NeoplasmsBenjamin Rolles, Ann Mullally
Blood|September 30, 2006
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantationAnn Mullally, Jerome Ritz
Hematology. American Society of Hematology. Education Program|December 4, 2018
JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapyMichele Ciboddo, Ann Mullally
Cell Stem Cell|September 10, 2013
Sinister symbiosis: pathological hematopoietic-stromal interactions in CMLAnn Mullally, Benjamin L Ebert
Journal of Visualized Experiments : Jove|January 25, 2018
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic CellsNouran S Abdelfattah, Ann Mullally
Blood|February 5, 2017
Myeloproliferative neoplasm stem cellsAdam J Mead, Ann Mullally
Blood|November 8, 2014
Hit the spleen, JAK!Steven W Lane, Ann Mullally
Frontiers in Immunology|September 28, 2020
Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPNJonas Samuel Jutzi, Ann Mullally
Pageof 7